Vascular and Oncology device company, AngioDynamics, points us at the publication of clinical data supporting the use of its NanoKnife®.
Pancreatic cancer has one of the highest mortality rates of all cancers and is expected to climb from the fourth leading cause of cancer-related death in the U.S. to the second by 2020. Ninety-four percent of pancreatic cancer patients will die within five years of diagnosis, and 74 percent of patients die within the first year of diagnosis.
AngioDynamics’ NanoKnife® System is designed for the ablation of soft tissue and is the first ablation system to use a series of high-voltage, but low-energy electrical pulses which are believed to permanently open pores in cell membranes.
Data from STAR (Soft Tissue Ablation Registry) utilizing NanoKnife®, is found in the September 2015 online edition of the peer-reviewed Annals of Surgery. The newly published paper is entitled: Treatment of 200 Locally Advanced (Stage III) Pancreatic Adenocarcinoma Patients With Irreversible Electroporation, Safety and Efficacy.
The goal of the study was to evaluate the effectiveness of IRE as a consolidative therapy in combination with chemotherapy and/or chemoradiation therapy in the management of LAPC.
A total of 200 patients with LAPC underwent IRE alone (n = 150) or pancreatic resection plus IRE for margin enhancements (n = 50). All patients underwent induction chemotherapy with 52 percent receiving chemo-radiation, for a median of seven months (range, 5-13) prior to IRE. IRE was successfully administered to all patients. Thirty-seven percent of patients sustained complications with a median grade of 2 (range 1-5). Median length of stay was six days (range, 4-36 days) with a median follow-up of 29 months. Six patients (3%) experienced local recurrence. Median overall survival in both groups was 24.9 months (range: 4.9 – 85 months).
The authors of the paper, led by Robert Martin, M.D., Ph.D., F.A.C.S., director of the Division of Surgical Oncology, and Professor, Department of Surgery, University of Louisville, James Graham Brown Cancer Center, stated in the paper’s conclusion that they believe, “IRE results in substantially prolonged survival of patients with LAPC compared with historical controls.”
Source: Globe Newswire